Accuracy of Established Prognostic Staging Systems for Cardiac Transthyretin Amyloidosis in the Tafamidis Era

Background: Biomarker-based prognostic staging systems, including the National Amyloidosis Centre (NAC) and the Mayo staging systems, are widely-used but have only been validated for treatment-naive patients with cardiac transthyretin amyloidosis (ATTR-CA). Objectives: The purpose of this study was...

Täydet tiedot

Bibliografiset tiedot

Päätekijät:	Maximilian Leo Müller, MD, Sebastian Spethmann, MD, Daniel Messroghli, MD, Anna Brand, MD, Isabel Mattig, MD, Katrin Hahn, MD, Ulf Landmesser, MD, Bettina Heidecker, MD
Aineistotyyppi:	Artigo
Kieli:	Inglês
Julkaistu:	Elsevier 2025-02-01
Sarja:	JACC: Advances
Aiheet:	ATTR-CA disease-modifying treatment estimated glomerular filtration rate (eGFR) high-sensitivity cardiac troponin T (hs-cTnT) N-terminal pro B-type natriuretic peptide (NT-proBNP) risk-stratification
Linkit:	http://www.sciencedirect.com/science/article/pii/S2772963X24008494
Tagit:	Lisää tagi Ei tageja, Lisää ensimmäinen tagi!